| Literature DB >> 31852795 |
Na Kong1,2, Wei Tao3, Xiang Ling1, Junqing Wang1, Yuling Xiao1, Sanjun Shi1, Xiaoyuan Ji1,4, Aram Shajii1, Silvia Tian Gan1,5, Na Yoon Kim1, Dan G Duda6, Tian Xie7, Omid C Farokhzad3,8, Jinjun Shi3.
Abstract
Loss of function in tumor suppressor genes is commonly associated with the onset/progression of cancer and treatment resistance. The p53 tumor suppressor gene, a master regulator of diverse cellular pathways, is frequently altered in various cancers, for example, in ~36% of hepatocellular carcinomas (HCCs) and ~68% of non-small cell lung cancers (NSCLCs). Current methods for restoration of p53 expression, including small molecules and DNA therapies, have yielded progressive success, but each has formidable drawbacks. Here, a redox-responsive nanoparticle (NP) platform is engineered for effective delivery of p53-encoding synthetic messenger RNA (mRNA). We demonstrate that the synthetic p53-mRNA NPs markedly delay the growth of p53-null HCC and NSCLC cells by inducing cell cycle arrest and apoptosis. We also reveal that p53 restoration markedly improves the sensitivity of these tumor cells to everolimus, a mammalian target of rapamycin (mTOR) inhibitor that failed to show clinical benefits in advanced HCC and NSCLC. Moreover, cotargeting of tumor-suppressing p53 and tumorigenic mTOR signaling pathways results in marked antitumor effects in vitro and in multiple animal models of HCC and NSCLC. Our findings indicate that restoration of tumor suppressors by the synthetic mRNA NP delivery strategy could be combined together with other therapies for potent combinatorial cancer treatment.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31852795 PMCID: PMC7024563 DOI: 10.1126/scitranslmed.aaw1565
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956